[H-2]DITOLYLGUANIDINE BINDING TO HUMAN BRAIN SIGMA SITES IS DIMINISHED AFTER HALOPERIDOL TREATMENT

被引:28
作者
REYNOLDS, GP [1 ]
BROWN, JE [1 ]
MIDDLEMISS, DN [1 ]
机构
[1] MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,HARLOW CM20 2QR,ENGLAND
关键词
D O I
10.1016/0014-2999(91)90110-C
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
[No abstract available]
引用
收藏
页码:235 / 236
页数:2
相关论文
共 5 条
[1]   NOVEL ANTIPSYCHOTIC-DRUGS SHARE HIGH-AFFINITY FOR SIGMA-RECEPTORS [J].
LARGENT, BL ;
WIKSTROM, H ;
SNOWMAN, AM ;
SNYDER, SH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 155 (03) :345-347
[2]  
LEE T, 1989, Society for Neuroscience Abstracts, V15, P1319
[3]  
RIVA M A, 1990, Molecular Neuropharmacology, V1, P17
[4]  
SIMPSON MDC, 1990, SCHIZOPHR RES, V3, P32
[5]   1,3-DI(2-[5-H-3]TOLYL)GUANIDINE - A SELECTIVE LIGAND THAT LABELS SIGMA-TYPE RECEPTORS FOR PSYCHOTOMIMETIC OPIATES AND ANTIPSYCHOTIC-DRUGS [J].
WEBER, E ;
SONDERS, M ;
QUARUM, M ;
MCLEAN, S ;
POU, S ;
KEANA, JFW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (22) :8784-8788